

# Weekly versus three-weekly docetaxel in women with breast cancer

<b>Submission date</b> 25/02/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 02/06/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 29/01/2016	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Background and study aims

Weekly doses of the drug docetaxel have occasionally been used to treat patients with breast cancer. The aim of this study is to compare the effect of weekly versus the standard three-weekly docetaxel treatment on patients' quality of life.

Who can participate?

Women aged 18 -70 with breast cancer.

What does the study involve?

After 4 cycles of doxorubicin and cyclophosphamide treatment, participants are randomly allocated to receive either 12 cycles of weekly docetaxel or 4 cycles of three-weekly docetaxel.

What are the possible benefits and risks of participating?

Weekly docetaxel may cause fewer side effects and therefore improve patients' quality of life. The common side effect of chemotherapy is febrile neutropenia (fever).

Where is the study run from?

Lincoln County Hospital (UK)

When is the study starting and how long is it expected to run for?

July 2000 to November 2002

Who is funding the study?

Sanofi Aventis (UK); Royal Thai Army, Bangkok (Thailand); Prince of Songkla University, Songkla (Thailand)

Who is the main contact?

Prof. Oleg Eremin  
oleg.eremin@ulh.nhs.uk

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Oleg Eremin

**Contact details**

Research & Development  
Lincoln County Hospital  
Greetwell Road  
Lincoln  
United Kingdom  
LN2 5QY

**Additional identifiers****Protocol serial number**

Trial 206(n) protocol 1.0

**Study information****Scientific Title**

A randomised controlled study of weekly versus three weekly docetaxel in women with breast cancer

**Study objectives**

The hypothesis was that weekly docetaxel versus three weekly regime resulted in comparable quality of life without compromising treatment efficacy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Nottinghamshire Research Ethics Committee, 05/04/2000, ref: 206(n)

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Primary breast cancer

**Interventions**

Arm A: 12 cycles of weekly docetaxel intravenously (IV) 100 mg/m<sup>2</sup> for 12 weeks treatment  
Arm B: 4 cycles of three-weekly docetaxel IV 100 mg/m<sup>2</sup> for 4 weeks treatment

Follow-up for both arms was 75.5 months.

**Intervention Type**

Drug

**Phase**

Phase II/III

**Drug/device/biological/vaccine name(s)**

Docetaxel

**Primary outcome(s)**

Quality of life 3 weeks after completion of chemotherapy

**Key secondary outcome(s)**

1. Clinical and pathological responses at 12 weeks
2. Disease free survival and overall survival at 5 years

**Completion date**

01/11/2002

**Eligibility****Key inclusion criteria**

1. Women aged 18 - 70 years
2. Unilateral/bilateral large (greater than or equal to 3 cm) or locally advanced primary breast cancer (T3, T4, TxN2), no distant metastases
3. World Health Organization (WHO) performance status of less than 2
4. Adequate cardiac, haematological, renal, and hepatic function

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

70 years

**Sex**

Female

**Key exclusion criteria**

1. Pregnant
2. Previous malignancy (except curatively treated carcinoma in situ of the cervix or basal cell carcinoma of skin)
3. Previous cytotoxic, endocrine, or radiotherapy
4. Active infection
5. Contraindications to corticosteroid administration
6. Pre-existing neurotoxicity (greater than grade 2) as defined by the National Cancer Institute Common Toxicity Criteria (NCI-CTC)
7. Significant cognitive impairment or dementia
8. Inability to complete quality of life (QoL) questionnaires or provide informed consent

**Date of first enrolment**

01/07/2000

**Date of final enrolment**

01/11/2002

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

Lincoln County Hospital

Lincoln

United Kingdom

LN2 5QY

## Sponsor information

**Organisation**

United Lincolnshire Hospitals NHS Trust (UK)

**ROR**

<https://ror.org/0377kyv52>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Sanofi-Aventis Pharmaceuticals (UK)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	18/05/2011		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes